StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Stifel on Neurocrine Bio. (NBIX): 'Really Nice Ingrezza Quarter, Guidance Starting to Look Potentially Conservative'
May 4, 2022 10:25 AM
Stifel analyst Paul Matteis reiterated a Buy rating and $136.00 price target on Neurocrine Bio. (NASDAQ: NBIX).The analyst comments "We ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Next Articles
Raymond James on Neurocrine Bio. (NBIX): 'Solid Beat for Ingrezza; Well Positioned Moving Forward'
May 4, 2022 10:24 AM
BMO Capital Maintains Underperform Rating on Neurocrine Bio (NBIX), "Outlook for Ingrezza Has Not Changed"
May 4, 2022 8:11 AM
Form 10-Q NEUROCRINE BIOSCIENCES For: Mar 31
May 4, 2022 7:42 AM
Form 8-K NEUROCRINE BIOSCIENCES For: May 04
May 4, 2022 7:38 AM
Neurocrine Biosciences (NBIX) Misses Q1 EPS by 5c
May 4, 2022 7:36 AM
Neurocrine Biosciences Reports First Quarter 2022 Financial Results and Reiterates 2022 Financial Guidance
May 4, 2022 7:30 AM
Neurocrine Biosciences to Present at the Bank of America Securities 2022 Healthcare Conference
May 3, 2022 4:01 PM
Neurocrine Biosciences Honors Mental Health Awareness Month and Fifth Anniversary of Tardive Dyskinesia Awareness Week
May 2, 2022 8:30 AM
